Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.
Publication
, Conference
Paul, B; Feinberg, D; Sundaramoorthy, P; Weinberg, JB; Kang, Y
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
8047 / 8047
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Paul, B., Feinberg, D., Sundaramoorthy, P., Weinberg, J. B., & Kang, Y. (2018). Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib. In Journal of Clinical Oncology (Vol. 36, pp. 8047–8047). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.8047
Paul, Barry, Daniel Feinberg, Pasupathi Sundaramoorthy, J Brice Weinberg, and Yubin Kang. “Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.” In Journal of Clinical Oncology, 36:8047–8047. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.8047.
Paul B, Feinberg D, Sundaramoorthy P, Weinberg JB, Kang Y. Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 8047–8047.
Paul, Barry, et al. “Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 8047–8047. Crossref, doi:10.1200/jco.2018.36.15_suppl.8047.
Paul B, Feinberg D, Sundaramoorthy P, Weinberg JB, Kang Y. Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 8047–8047.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
8047 / 8047
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences